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BACKGROUND: Cigarette smoking is an important risk
factor for adverse health events in HIV-infected popula-
tions. While recent US population-wide surveys report
annual sustained smoking cessation rates of 3.4–8.5%,
prospective data are lacking on cessation rates for HIV-
infected smokers.
OBJECTIVE: To determine the sustained tobacco ces-
sation rate and predictors of cessation among women
with or at risk for HIV infection.
DESIGN: Prospective cohort study.
PARTICIPANTS: A total of 747 women (537 HIV-
infected and 210 HIV-uninfected) who reported smoking
at enrollment (1994–1995) in the Women’s Interagency
HIV Study (WIHS) and remained in follow-up after
10 years. The participants were mostly minority (61%
non-Hispanic Blacks and 22% Hispanics) and low
income (68% with reported annual incomes of less than
or equal to $12,000).
MEASUREMENTS AND MAIN RESULTS: The primary
outcome was defined as greater than 12 months con-
tinuous cessation at year 10. Multivariate logistic
regression was used to identify independent baseline
predictors of subsequent tobacco cessation. A total of
121 (16%) women reported tobacco cessation at year 10
(annual sustained cessation rate of 1.8%, 95% CI 1.6–
2.1%). Annual sustained cessation rates were 1.8%
among both HIV-positive and HIV-negative women (p=
0.82). In multivariate analysis, the odds of tobacco
cessation were significantly higher in women with more
years of education (p trend=0.02) and of Hispanic origin
(OR=1.87, 95% CI=1.4–2.9) compared to Black women.
Cessation was significantly lower in current or former
illicit drug users (OR=0.42 95% CI=0.24–0.74 and OR=
0.65, 95% CI=0.49–0.86, respectively, p trend=0.03)
and women reporting a higher number of cigarettes per
day at baseline (p trend<0.001).
CONCLUSIONS: HIV-infected and at-risk women in this
cohort have lower smoking cessation rates than the
general population. Given the high prevalence of smok-
ing, the high risk of adverse health events from
smoking, and low rates of cessation, it is imperative
that we increase efforts and overcome barriers to help
these women quit smoking.
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INTRODUCTION
Smoking is common among HIV-infected people, with surveys
showing consistent smoking rates above 45% and as high as
74%.
1–3 The widespread use of anti-retroviral therapies has
resulted in a dramatic reduction of HIV-related morbidity and
mortality.
4,5 Improvements in the care and longevity of persons
with HIV have increased the attention on smoking cessation
for HIV-infected individuals.
1,2,6
There are overlapping hazards of HIV infection, its treat-
ment, and smoking that draw attention to smoking as a
modifiable risk factor. Smoking has been reported to be
independently associated with adverse HIV-related outcomes
in the context of HAART, including the development of clinical
AIDS, lower CD4 counts, a trend toward higher viral loads
7,
and poorer health-related quality of life.
8,9 The cardiovascular
risk of smoking is important since HIV-infected individuals
may have more extensive sub-clinical atherosclerosis com-
pared to HIV-uninfected individuals,
10 and protease inhibitors
may confer cardiovascular risk.
11,12 Initial studies reported
increased risk of lung cancer among HIV-infected individuals
independent of tobacco use
13 and earlier diagnosis of late-
stage lung cancers in HIV-infected individuals with lower
smoking exposure.
14 HIV infection is an independent risk
factor for chronic obstructive pulmonary disease.
15
While smoking rates are high and the risk of smoking-
related morbidity is increased, little is known about smoking
cessation in HIV-infected individuals. In surveys among HIV-
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39infected individuals who ever smoked, 22%-39% were absti-
nent at the time they were surveyed
9,16–18 compared to 52% in
the general population.
19 These cross-sectional data, while
suggestive of less cessation, do not adequately assess cessa-
tion rates of HIV-infected smokers.
Published estimates of annual sustained cessation deter-
mined from population-based US surveys range from 3.4 to
8.5% per year.
20,21 During the decade of the 1990s, data from
the Tobacco Use Supplement to the Current Population Survey
showed that the annual rate of 12-month sustained smoking
cessation among non-Hispanic Whites was 3.4%.
20 A more
recent analysis of the 2003 Current Population Survey showed
6-month population-wide sustained cessation ranging from
5.0 to 8.5% among various age groupings.
21
The Women’s Interagency HIV Study (WIHS) is a longitudi-
nal cohort study of women with and at risk for HIV. As smoking
status is tracked in WIHS, it provides a unique opportunity to
determine the annual rate of sustained smoking cessation.
Similar to other cohorts of HIV-infected persons, the baseline
rate of smoking among the HIV-infected women in WIHS was
56%. The rate of smoking among the HIV-uninfected women in
WIHS was 63%.
22 The high rate of smoking among both the
HIV-infected and HIV-uninfected women in WIHS likely reflects
the presence of life stressors including poverty, substance use,
and depression.
23,24
In this study, we describe the annual rate of sustained
tobacco cessation among surviving women in WIHS who
smoked at baseline and were followed for 10 years. This study
aims to compare smoking cessation rates among women with
or at risk for HIV infection to the US population. We also
describe baseline demographic, psychosocial, and smoking-
related predictors of sustained cessation for women in WIHS.
METHODS
The overall aim of the Women’s Interagency HIV Study (WIHS)
is to examine HIV disease progression in women, including
how clinical and psychosocial variables are associated with
HIV-related disease outcomes. In 1994 and 1995, WIHS
recruited 2,626 women with confirmed HIV sero-status:
2,058 were HIV-infected and 568 were HIV-uninfected. The
participants were recruited from HIV treatment programs,
drug treatment programs, HIV testing sites, community out-
reach, and referral from participants. The study methods were
described previously.
23 The Institutional Review Boards of the
six participating centers approved all study protocols and
participants completed written informed consent at baseline
and annually.
At the time of enrollment, participants in WIHS were at least
13 years old, agreed to testing and counseling for HIVinfection,
spoke English or Spanish, and completed the baseline assess-
ments. The baseline assessment included questionnaires of
demographics, physical and psychological health status, sex-
ual behavior, health care utilization, and substance and
tobacco use. Each semi-annual follow-up visit included similar
assessments, and participants received monetary compensa-
tion at each visit. At baseline, a current smoker included
women who responded “Yes” to the question “Do you currently
smoke?” and reported a lifetime history of smoking at least 100
cigarettes. At follow-up study visits, women who reported
smoking at prior interviews and not smoking at the current
interview were questioned to determine the month and year of
their last cigarette.
The primary outcome of sustained cigarette smoking cessa-
tion is defined as greater than 12 months of self-reported
continuous cessation at year 10. The average annual rate of
sustained cessation was calculated by dividing the rate of
cessation at year 10 by 9, reflecting the 9 years of observation
when the cessation could be initiated. In unadjusted analyses
of baseline predictors of cessation, we used chi-square and
Mantel-Haenzel chi-square tests for nominal and ordinal
categorical predictors, respectively. We conducted significance
testing via chi-square to examine pairwise differences between
ethnic/racial groups. The p-trend for ordinal variables with
three or more categories was calculated using the Mantel-
Haenszel chi-square test for trend statistic. Predictors with a
p-value of <0.10 in unadjusted analyses were included in a
backward stepwise multivariate logistic regression model to
identify variables that remained significant (p<0.05) indepen-
dent predictors of sustained tobacco cessation.
RESULTS
The smoking status at the time of the year 10 interview was
available for 747 (50%) of 1,503 baseline smokers. Baseline
smokers no longer in follow-up at year 10 (n=756) included
514 (68%) women who dropped out of the study immediately
after the baseline visit, 14 (2%) women who had only one
incomplete follow-up interview without smoking data beyond
baseline, 134 (18%) women who died prior to the year-10
interview, and 94 (12%) surviving women remaining in the
study who did not have a year-10 assessment.
The baseline characteristics of the 747 women included in
this study are shown in Table 1. The mean and median age was
36. The majority were HIV-infected (74%), non-Hispanic Black
(61%), unemployed (83%), and with reported annual incomes
of less than or equal to $12,000 (68%). Depressive symptoms
(Center for Epidemiologic Studies; depression scores 16, 56%)
and current (41%) or former (43%) use of crack, cocaine, or
heroin were common. The majority had insurance (77%), most
of the insured had Medicaid or Medical (81%), while fewer had
private insurance (14%) or Medicare (4%).
Compared to the 756 baseline smokers not included in the
analysis, the women in our study were more likely HIV-
uninfected (28% vs. 20%, p<0.001), younger (median years of
age at baseline 36 vs. 38, p<0.001), with stable housing (71%
vs. 65%, p<0.05), employed (17% vs. 12%, p=0.01), smoked
for fewer years (median years smoked at baseline 17 vs. 20, p<
0.001), lighter smokers (≤10 cigarettes per day, 59% vs. 53%,
p=<0.05), and were less likely non-Hispanic White (14% vs.
20%, p<0.05) than non-Hispanic Black or Hispanic.
At the year-10 follow-up interviews, 121 (16%) women
reported smoking cessation of greater than 12 months for an
average annual sustained cessation rate of 1.8% (95% CI 1.6–
2.1%) per year. At the year-10 interview, an additional 8.8% of
women reported short-term cessation including 12 (1.6%)
women who reported quitting smoking for less than 1 month,
26 (3.5%) women who quit for 1–6 months, and 28 (3.7%)
women who quit for 6–12 months. The estimated average
annual rate of smoking cessation for 6 months or more (n=
149) was 2.2% (95% CI 1.9–2.5).
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WIHS Baseline and Remained in Study Follow-Up After 10 Years
Baseline characteristics N (%) at
Baseline
% Reporting
tobacco cessation
% Annual cessation
(95% CI)
Unadjusted
OR (95% CI)
Total 747 (100) 16 1.8 (1.6–2.1)
Study center Washington DC 90 (12) 12 1.3 (0.6–2.1) 1.00
Bronx 195 (26) 16 1.8 (1.2–2.4) 1.41 (0.68–2.94)
Brooklyn 121 (16) 14 1.6 (0.9–2.2) 1.17 (0.52–2.65)
Los Angeles 102 (14) 24 2.7 (1.7–3.5) 2.21 (1.01–4.82)
San Francisco 139 (19) 14 1.6 (0.9–2.2) 1.14 (0.51–2.52)
Chicago 100 (13) 18 2.0 (1.2–2.8) 1.58 (0.70–3.55)
HIV status Infected 537 (74) 16 1.8 (1.5–2.2) 1.00
Uninfected 210 (26) 16 1.8 (1.2–2.3) 1.05 (0.68–1.63)
Age (years) 18–30 156(21) 16 1.8 (1.1–2.4) 1.00
31–40 378 (51) 18 2.0 (1.5–2.4) 0.90 (0.68–1.19)
41–62 213 (29) 14 1.6 (1.0–2.0) 0.81 (0.46–1.41)
p trend=0.46
Ethnicity and race Non-Hispanic Black 456 (61) 13 1.4 (1.1–1.8) 1.00
Non-Hispanic White 108 (14) 19 2.1 (1.2–2.9) 1.47 (0.85–2.57)
Hispanic 165 (22) 22 2.4 (1.8–3.2) 1.87 (1.19–2.95)
Education level Less than high school 304 (41) 13 1.4 (1.0–1.8) 1.00
High school graduate 244 (33) 17 1.9 (1.3–2.4) 1.33 (1.05–1.69)
Beyond high school 199 (27) 21 2.3 (1.7–2.9) 1.76 (1.09–2.85)
p trend=0.02
Marital status Separated/divorced/
widowed
206 (28) 17 1.9 (1.3–2.5) 1.00
Married/cohabitating 280 (37) 17 1.9 (1.4–2.4) 1.01 (0.63–1.63)
Single/never married 253 (34) 15 1.7 (1.1–2.1) 0.84 (0.51–1.39)
Residential housing Unstable 216 (29) 13 1.4 (1.0–2.0) 1.00
Stable 531 (71) 17 1.9 (1.6–2.3) 1.35 (0.86–2.12)
Employment status Unemployed 621 (83) 16 1.8 (1.4–2.1) 1.00
Employed 125 (17) 19 2.1 (1.4–2.9) 1.28 (0.78–2.11)
Health insurance status Uninsured 167 (22) 13 1.4 (0.8–2.0) 1.00
Insured 575 (77) 17 1.9 (1.6–2.3) 1.46 (0.88–2.43)
Income ≤$12,000 505 (68) 15 1.7 (1.4–2.1) 1.00
>$12,000 203 (27) 17 1.9 (1.3–2.4) 1.10 (0.71–1.71)
Having a usual source of medical care No 108 (15) 13 1.4 (0.7–2.1) 1.00
Yes 634 (85) 17 1.9 (1.6–2.2) 1.36 (0.75–2.48)
Hospitalized in past 6 months No 600 (80) 17 1.9 (1.6–2.2) 1.00
Yes 146 (20) 13 1.4 (0.8–2.1) 0.73 (0.43–1.04)
CESD score <16 310 (41) 19 2.1 (1.7–2.6) 1.00
≥16 422 (56) 14 1.6 (1.2–2.0) 0.70 (0.48–1.04)
Heavy alcohol use Never 282 (38) 18 2.0 (1.5–2.6) 1.00
Former 351 (47) 15 1.7 (1.3–2.1) 0.82 (0.61–1.10)
Current 97 (13) 13 1.4 (0.7–2.2) 0.67 (0.37–1.22)
p trend=0.19
Marijuana use Never 117 (16) 17 1.9 (1.1–2.7) 1.00
Former 394 (53) 16 1.8 (1.4–2.2) 0.97 (0.73–1.30)
Current 236 (32) 16 1.8 (1.3–2.3) 0.95 (0.53–1.69)
p trend=0.85
Crack, cocaine, or heroin use Never 118 (16) 26 2.9 (2.0–3.8) 1.00
Former 319 (43) 18 2.0 (1.5–2.5) 0.58 (0.44–0.76)
Current 310 (41) 11 1.2 (0.8–1.6) 0.33 (0.19–0.57)
p trend<0.001
IV drugs use Never 378 (51) 17 1.9 (1.5–2.4) 1.00
Former 260 (35) 17 1.9 (1.4–2.4) 0.80 (0.60–1.06)
Current 109 (15) 10 1.1 (0.5–1.8) 0.64 (0.36–1.12)
p trend=0.12
Average number of cigarettes/day ≤10 443 (59) 20 2.2 (1.8–2.6) 1.00
11–20 247 (33) 12 1.3 (0.9–1.8) 0.51 (0.35–0.74)
≥20 56 (8) 5 0.6 (0.0–1.3) 0.26 (0.12–0.54)
p trend=0.003
Number of years since beginning smoking 0–5 78 (10) 27 3.0 (1.9–4.1) 1.00
6–10 107 (14) 22 2.4 (1.6–3.4) 0.81 (0.71–0.92)
11–15 152 (20) 15 1.7 (1.0–2.3) 0.65 (0.51–0.84)
16–20 170 (23) 12 1.3 (0.8–1.9) 0.53 (0.36–0.77)
21–25 122 (16) 17 1.9 (1.2–2.7) 0.43 (0.26–0.71)
≥26 118 (16) 9 1.0 (0.5–1.6) 0.34 (0.18–0.65)
p trend=0.001
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throughout the 9 years of observation; 58 women reporting
initiation of cessation during years 1–4 of the study, with 7
quitting during year 5, and 55 quitting during years 6–9. The
timeframe of initiation of cessation was similar among HIV-
infected and HIV-uninfected women (data not shown).
In the unadjusted analysis (Table 1), women from the Los
Angeles center were more likely to quit smoking compared to
women from the Washington DC site (OR=2.21, 95% CI 1.01–
4.82), reflecting the extremes of the 1.3% to 2.7% in annual
cessation rates across the study centers. In pairwise compar-
isons of Black, Hispanic, and White women, only Hispanic
women were more likely to quit using tobacco compared to
Black women (OR=1.87, 95% CI 1.19–2.95). Women with
education beyond high school were more likely to quit (OR=
1.76, 95% CI 1.09–2.85), as were high school graduates (OR=
1.33, 95% CI 1.05–1.69), when compared to women without a
high school degree. There was a gradient of increased cessation
across the categories of increasing education (p-trend=0.02).
Tobacco cessation was lower in women with depressive symp-
toms (OR=0.70, 95% CI 0.48–1.04). Cessation was not associ-
ated with alcohol or marijuana use; however, it was lower in
those who reported current use of other illicit drugs (OR=0.33,
95% CI 0.19–0.57) or former use (OR=0.58, 95% CI 0.44–0.76)
compared to never users. Tobacco cessation decreased signifi-
cantly across the categories of never, former, and current illicit
drug use (p-trend<0.001). Cessation decreased with increasing
number of cigarettes smoked per day (p-trend=0.003) and with
increasing years of smoking (p-trend=0.001).
HIV serostatus did not predict cessation. Being married,
being employed, having health insurance, or having a usual
source of medical care was not associated with odds of
cessation.
In adjusted analyses (Table 2), Hispanic women were more
likely to have sustained cessation than non-Hispanic Blacks
(OR=2.07, 95% CI 1.28–3.35). Women with more education
were more likely to quit smoking (p-trend=0.02). Current (OR=
0.43 95% CI=0.24–0.75) and former (OR=0.65, 95% CI 0.49–
0.86) users of crack, cocaine, or heroin and those smoking
more cigarettes daily (p-trend<0.001 for increasing number of
cigarettes) were significantly less likely to quit smoking
compared to those who never used these substances or who
smoked fewer cigarettes each day. The study center, depressive
symptoms, and years of tobacco smoking were not associated
with cessation in multivariate analyses.
DISCUSSION
Our results demonstrate that the cessation rate among women
in WIHS was lower than in US population-based studies. Non-
Hispanic Blacks, users of crack, cocaine, or heroin, women
with less education, and women smoking more cigarettes on a
daily basis were less likely to quit smoking. There were similar
rates of sustained smoking cessation among HIV-infected and
at-risk HIV-uninfected women.
We used 12 months of tobacco cessation as our primary
outcome; this duration of cessation has been recommended as
a stringent criterion approximating lifelong abstinence.
25 This
recommendation is based upon data from the California
Tobacco Survey. Former smokers identified at a baseline
interview were re-interviewed after 18 months. Those who
reported duration of cessation at the baseline interview of at
least 12 months and as long as more than 10 years had a
likelihood of 98% for the subsequent status of cessation (95%
continuous and 3% with relapse and subsequent quit), while
cessation less than 12 months had a likelihood of 66% for the
subsequent status of cessation (42% continuous cessation and
24% with relapse and subsequent quit).
26
While smoking prevalence is regularly tracked,
19 popula-
tion-based cessation is infrequently reported. There are two
recent publications describing US population-based cessation
rates. Messer
20 analyzed four waves of the Tobacco Use
Supplement of the Current Population Survey between 1992
and 2002. The analysis, restricted to non-Hispanic Whites
aged 20 to 64 years, reported 12-month sustained cessation.
The average annual cessation rate was 3.4%. Overall there was
increasing cessation during the 1990s with the most pro-
nounced acceleration among young smokers. The cessation
rates in California, New York, and New Jersey were higher (3.6
to 4.7% per year) compared to the tobacco growing states
(Kentucky, Tennessee, North Carolina, South Carolina, Virgi-
nia, and Georgia) (2.8 to 4.2% per year). Gender-specific rates
were not reported. The rates of cessation in the WIHS cohort,
applying a similar definition of sustained cessation during this
largely overlapping time period, were lower overall (1.8%) for
non-Hispanic Whites (2.1%), and for the California and New
York centers (1.6 to 2.7%).
In a second study, Messer
21 reported 6-month sustained
cessation rates in the 2003 Current Population Survey. This
analysis of 18 to 64 year olds included all race and ethnic
groups. It reported cessation by age, with rates of 8.5%, 7.0%,
5.0%, and 5.1% for the age groups of 18–24, 25–34, 35–49,
and 50–64, respectively. Women (1.16), African Americans
(0.63), and Hispanics (0.86) had non-significant adjusted odds
ratios of cessation. In WIHS, the rate of 6-month sustained
cessation was lower at 2.2%.
While several predictors of cessation were identified in this
study, cessation rates were low even among those identified as
Table 2. Baseline Characteristics Associated with Tobacco
Cessation in Multivariate Analysis of 10-Year Follow-Up Among
HIV-Infected and HIV-Uninfected Smokers in the WIHS
Baseline
characteristics
Adjusted
odds ratio
95% CI P for
trend
Ethnicity and race
Non-Hispanic Black 1.00
Non-Hispanic White 1.53 0.85–2.75
Hispanic 2.07 1.28–3.35
Education
Less than high school 1.00
High school graduate 1.37 1.06–1.76 0.02
Beyond high school 1.87 1.13–3.12
Crack/cocaine/heroin use
Never 1.00
Former 0.65 0.49–0.86 0.003
Current 0.43 0.24–0.74
Cigarettes smoked/day
≤10 1.00
11–20 0.50 0.34–0.74 <0.001
>20 0.25 0.12–0.55
Variables included in the multivariate model included study center;
ethnicity; education; CES-D score; crack, cocaine, or heroin use; average
number of cigarettes/day; and number of years since beginning smoking
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more than high school education (2.3%), and those without
crack, cocaine, or heroin use (2.9%). In our study, HIV status
did not predict cessation, likely due to the similar socio-
demographic characteristics of the HIV-infected and HIV-
uninfected women in WIHS. It appeared that the rate of
initiation of the sustained cessation among HIV-infected
women was not different during the pre-HAART and early
HAART eras. Having a usual source of medical care did not
predict cessation.
The low rates of sustained cessation add support to calls for
increased attention to smoking cessation services in medical
care settings for women with HIV and at risk for HIV.
1,2,6 For
this service development, we should consider how gender,
race/ethnicity, and social class influence smoking cessa-
tion,
27–29 including knowledge of cessation benefits,
24 social
and environmental support for cessation,
30 and awareness of
and access to integrated counseling and pharmacothera-
py.
31,32 In addition, we believe that the clinical implication of
drug use warrants consideration as a predictor of poor
cessation outcomes. Histories of substance use are common
among individuals who smoke and are HIV-infected or at risk
(in this study there were 84% with current or former illicit drug
use). There is an emerging consensus that smoking cessation
programs for individuals in substance use treatment or
recovery are effective and may enhance substance use treat-
ment.
33,34 However, there are limitations to the research
studying tobacco cessation and substance use. Published
studies of smoking cessation and substance use outcomes
are set in treatment programs for dependence disorders. The
studies of smokers with remote substance use are limited to
recovering alcoholics. We are unaware of smoking cessation
outcomes research studying individuals with a variety of
substances used and with current and/or prior dependent
and non-dependent use of substances to guide primary care of
smoking cessation.
Furthermore, our analyses suggest that public health
strategies, such as the California Tobacco Control Program,
started in 1989 and focusing on changing population-wide
social norms, knowledge, and public policy,
35 may not have
penetrated this demographic of women, as we did not find
differences in cessation based upon the participants’ state of
residence. It may be important to determine how social
marketing strategies may alter smoking acceptability among
those with HIV risk. As we come to understand the importance
of social networks on cessation,
36 it is plausible that women
who are HIV-infected or at risk are not part of social networks
in which family members, friends, or co-workers have quit
smoking.
30
There are limitations to our findings. There were demo-
graphic and smoking-related differences between those with
and without follow-up data, limiting the generalizability of the
findings. The loss of follow-up is mostly due to the large
number of women who had only a baseline study interview and
secondarily due to women who died during the 10 years of
follow-up. We had complete data on 89% of 841 surviving
women with any follow-up data. Given that WHIS enrollees
who were not included in this study were heavier and longer
duration smokers, we believe that it is unlikely that women
lost to follow-up had higher rates of sustained smoking
cessation. Their loss to follow-up should not detract from our
conclusion that HIV-infected and at-risk women have lower
cessation rates than the US population. A second limitation of
the study is that we used only baseline data as predictors of
cessation. It is conceivable that there were time varying effects of
variables that influenced cessation not captured by this analy-
sis. We used only the year-10 cessation as the outcome variable.
There may have been some women who quit smoking for more
than 12 months and subsequently relapsed who were classified
in the group that did not achieve sustained cessation.
While we assessed having a usual source of medical care as
a predictor of cessation and the WIHS study centers advised
and encouraged cessation and referred all participants to
primary care providers, in this analysis, we are unable to
determine if medical care remained stable over time or if
utilization affected cessation. This analysis covers the period of
time immediately before and during the dissemination of
HAART therapy. It is conceivable that simpler, contemporary
HAART regimens may have changed the dynamic of smoking
cessation among HIV-infected women in ways that we were
unable to measure. Finally, there may be unmeasured media-
tors of cessation.
31
The care of women with HIV and at risk for HIV is complex,
with numerous medical, behavioral, and psychosocial dimen-
sions related to their needs for substance use treatment, safe
sex practices, stable housing, depression treatment, and med-
ication adherence. It is possible that the low cessation rates
reflect this difficult and competing set of needs for patients and
their providers. While sustained cessation is lower among the
women in WIHS than the general population, we do not know if
they made fewer cessation attempts and if their cessation efforts
were more likely to result in relapse. Future analyses using time
varying longitudinal techniques, extending the analyses beyond
the first 10 years of WIHS, and that assess short-term cessation
and relapse are likely to help us understand the chain of events
with respect to cessation in WIHS and define barriers to
initiating and maintaining cessation.
Forty years after the first Surgeon General’s report on
smoking and health,
37 there has been a multi-faceted anti-
smoking campaign throughout the United States. We have
witnessed the dissemination of clinical interventions, medica-
tions, and public health policies and programs that aid
cessation. Among adult women, the rate of smoking declined
from 34% in 1964
38 to 17% in 2007.
19 However, for women
with and at high risk for HIV infection, the current rates of
smoking dwarf those of US women in the 1960s, the smoking-
related risk are increased in the presence of HIV, and the rate
of cessation among HIV-infected and at-risk women is well
below that of the population at large. To avert predictable
smoking-related morbidity and mortality, it is imperative that
we intensify efforts to help these high-risk women quit
smoking.
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